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Abstract. The stability of oligodeoxynucleotides to trifluoroacetic acid is studied. 
Pyrimidine oligonucleotides were stable in the conditions used for the removal of t-
butyl groups. Oligonucleotide-3’-peptide conjugates carrying pyrimidine 
oligonucleotides are prepared stepwise using peptide-supports and Fmoc, t-butyl 
strategy. Using this strategy we have prepared an oligonucleotide-peptide conjugate 
containing as peptide the leucine-rich fragment of FOS, a transcription factor involved 
in many important cellular processes. This conjugate has a long peptide sequence with a 
large number of trifunctional amino acids. 
 Introduction. The use of synthetic oligonucleotides to control gene expression has 
triggered the search for new oligonucleotide derivatives with improved therapeutic 
potential[1]. Oligonucleotide-peptide conjugates are chimeric molecules consisting of 
oligonucleotides covalently linked to peptides. As a result, synthetic oligonucleotides 
acquire some of the biological and/or biophysical properties of peptides.  
Two strategies can be followed to synthesize oligonucleotide-peptide conjugates[2]. In 
the post-synthetic conjugation approach, the two moieties are prepared independently 
and specific groups (such as thiols and maleimido) are specifically incorporated to link 
both molecules[3]. In the stepwise approach, oligonucleotide-peptide conjugates are 
prepared by stepwise addition of amino acids and phosphoramidites in solid phase on 
the same solid support[4]. In this case, the problem is the incompatibility of the standard 
schemes of protection for peptides and oligonucleotides. For example, at the end of the 
solid-phase peptide synthesis, a treatment with acid is usually required, which can 
provoke partial depurination of DNA.  
Recently, our group has undertaken the preparation of conjugates consisting of double-
stranded DNA (dsDNA) and selected fragments of biologically relevant transcription 
factors. Specifically we focused on the synthesis of conjugates between DNA and 
peptidic regions from the leucine zipper domain of FOS[5]. These constructs, which 
display a dual recognition surface provided by the presence of both the peptide and the 
DNA, were devised as potential specific receptors for  selected FOS partners, such as 
the well known oncogenic transcription factor JUN. Hypothetically, the recognition 
would involve a specific interaction between the leucine-rich region of JUN and the 
hybrid, and an additional interaction between the oligonucleotide portion of the 
constructs and the basic region of JUN[6]. The synthesis of these conjugates is difficult 
due to the presence of long peptide sequences with large number of trifunctional amino 
acids. In any case we evaluated the viability of making this type of oligonucleotide-
peptide conjugates using a stepwise Fmoc, t-butyl strategy.  
 
Results and Discussion.  
 
Stability of oligodeoxynucleotides to trifluoroacetic acid. Trifluoroacetic acid (TFA) is a 
strong acid commonly used in the final deprotection step of peptide synthesis using 
Fmoc-amino acids.  It is known that acidic solutions provoke depurination of purine 
nucleosides. On the other hand, depurination is slower in oligonucleotides and indeed 
several experiments on the use of TFA to remove Boc groups in the presence of 
oligodeoxynucleotides were described almost two decades ago[7,8]. In order to study the 
extension of this reaction we have treated 4 oligodeoxynucleotide sequences (T9, T4CT4, 
T4AT4 and T4GT4) with 95% TFA aqueous solution. Two different treatments were 
studied. Treatment A: The oligonucleotide supports (polystyrene, LV200) obtained after 
the assembly of the oligonucleotide sequence still carrying the protecting groups were 
treated with 95% TFA aqueous solution. After 2 hours, the acidic solution was filtered 
out and the support was treated with concentrated ammonia. The resulting solution was 
concentrated to dryness and analyzed by reversed-phase HPLC. Treatment B: 
Oligonucleotides were deprotected with ammonia and the resulting unprotected 
oligonucleotides were treated with 95% TFA aqueous solution for 2 hours. The 
resulting solutions were concentrated to dryness, treated with ammonia (to break 
apurinic sites) and analyzed by HPLC.  
Pyrimidine oligonucleotides (T9 and T4CT4), after treatment A, gave a single peak with 
the expected mass by MALDI MS, indicating stability of the oligonucleotides to the 
TFA treatment as it is expected due to the higher stability of the glycosidic bond of 
pyrimidine nucleosides. Exceptionally, treatment B on T4CT4 with TFA promoted a 
slight decomposition. Oligonucleotide sequence carrying adenine (T4AT4) gave two 
more peaks eluting before the peak of the initial oligonucleotide (Figure 1). This 
indicates loss of the adenine followed by hydrolysis of phosphate at the abasic site by 
ammonia. The extension of the depurination was around 80% in treatment A and 60% 
in treatment B. Oligonucleotide sequence carrying guanine (T4GT4) was stable to 
treatment A but unstable to treatment B (30% depurination). This is consistent with the 
higher stability of dG to depurination compared to dA. Depurination was more severe in 
treatment B probably because in solution reactions are faster and because of the 
additional time of exposure to acids during concentration of the solution. 
 
Synthesis of pyrimidine oligonucleotide conjugates carrying the leucine zipper domain 
of FOS. The stability of pyrimidine oligodeoxynucleotides to TFA suggest that 
pyrimidine oligonucleotide conjugates may be prepared by addition of the 
oligonucleotide sequence to the peptide support carrying the leucine zipper domain of 
FOS assembled with the standard Fmoc, tBu-strategy. Scheme 1 outlines the synthetic 
approach. The peptide part is a peptide of 35 amino acids carrying 25 trifunctional 
amino acids, two of which are arginines. The oligonucleotide moiety is 
tridecathymidine. 
The synthesis of the 35 amino acid peptide was carried out manually on a Rink-
MBHA amide resin using Fmoc-protected amino acids and a symmetric anhydride 
strategy.  In order to incorporate the oligonucleotide sequence to the peptide support, 
the amino terminal group was reacted with the O-4-trityl derivative of 4-
hydroxybutanoic acid. This compound will generate the hydroxyl group which will be 
used to assemble the oligonucleotide sequence (Scheme 1). Figure 2 shows the HPLC 
analysis of the T13-leucine zipper domain conjugate (Waters X-Terra column at a flow 
rate of 1 mL/min, detection 260 nm, gradient 15-80% B in 20 min, A: 5% CH3CN in 
100 mM TEAA pH 7.0, B: 70% CH3CN in 100 mM TEAA pH 7.0). A major peak 
corresponding to the desired conjugate was observed and characterized by UV, PAGE 
and MALDI MS. To the best of our knowledge these conjugates are among the largest 
and more complex oligonucleotide-peptide conjugates constructed to date by chemical 
synthesis, and in particular by solid-supported stepwise methods. 
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FIGURES AND SCHEMES 
 
Scheme 1. Outline of the synthesis of oligonucleotide conjugate T13-leucine zipper 
domain by the stepwise approach. 
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Figure 1. HPLC of the mixture resulting from the treatment of the support carrying 
T4AT4 followed by ammonia deprotection. The late-eluting peak is the remaining full-
length oligonucleotide sequence T4AT4. HPLC conditions as follows. Nucleosil 120 
C18 (250 x 8 mmm) column at a flow rate of 3 mL/min, detection 260 nm, gradient 0-
50% B in 20 min, A: 5% CH3CN in 100 mM triethylammonium acetate (TEAA) pH 
7.0, B: 70% CH3CN in 100 mM TEAA pH 7.0. 
 
 
 
 
 
 
 
Figure 2. HPLC purification of oligonucleotide conjugate T13-leucine zipper domain. 
The peak at 10.9 min is the expected oligonucleotide conjugate. HPLC conditions in the 
insert. 
 
  
HPLC conditions
Analytical C18  X-Terra column
A: H2O/CH3CN (95:5) 0.1 M TEAA
B: CH3CN/H2O (70:30) 0.1 M TEAA
Gradient 15-80% B in 20 min
Detection 260 nm
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